SCHEMBL5879256

SCHEMBL5879256

Cc1ccc2c(c1)[nH]c1c3c(=O)[nH]c(=O)c3c3c(=O)[nH]c(=O)c3c21

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 6/20 0.63
CDK4 P11802 2/20 0.52
CCND1 P24385 2/20 0.52
CAMK2B Q13554 1/20 0.52
CAMK2G Q13555 1/20 0.52
CAMK2D Q13557 1/20 0.52
CAMK2A Q9UQM7 1/20 0.52
KIF11 P52732 2/20 0.44
GABRP O00591 1/20 0.43
GABRD O14764 1/20 0.43
GABRA1 P14867 1/20 0.43
GABRB1 P18505 1/20 0.43
GABRG2 P18507 1/20 0.43
GABRB3 P28472 1/20 0.43
GABRA5 P31644 1/20 0.43
GABRA3 P34903 1/20 0.43
GABRA2 P47869 1/20 0.43
GABRB2 P47870 1/20 0.43
GABRA4 P48169 1/20 0.43
GABRE P78334 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5879181 0.86 CHEK1 (0.82) CHEK1ALDH1A1RXFP1MAPT
SCHEMBL21563914 0.80 CDK4 (0.53) CHEK1CDK4CCND1CAMK2BCAMK2G
SCHEMBL6201746 0.79 CHEK1 (0.59) CHEK1CDK4CCND1CAMK2BCAMK2G
SCHEMBL5879261 0.79 CHEK1 (0.59) CHEK1CDK4CCND1CAMK2BCAMK2G
SCHEMBL5879318 0.79 CHEK1 (0.59) CHEK1CDK4CCND1CAMK2BCAMK2G
SCHEMBL5879202 0.79 CDK4 (0.62) CHEK1CDK4CCND1CAMK2BCAMK2G
SCHEMBL29022540 0.77 CHEK1 (0.56) CHEK1CDK4CCND1CAMK2BCAMK2G
SCHEMBL8873683 0.76 KIF11 (0.52) CDK4CCND1CAMK2BCAMK2GCAMK2D
SCHEMBL14431320 0.76 CDK4 (0.59) CHEK1CDK4CCND1CAMK2BCAMK2G
SCHEMBL22567015 0.75 CDK4 (0.86) CHEK1CDK4CCND1CAMK2BCAMK2G

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7151108-B2 Anticarcinogenic, antiproliferative, and antitumor agents LES LABORATORIES SERVIER (FR) 2006-12-19 US disclosed
EP-1411057-B1 [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2005-04-27 EP disclosed
US-20040077672-A1 Anticarcinogenic, antiproliferative, and antitumor agents LES LABORATOIRES SERVIER (FR) 2004-04-22 US disclosed
EP-1411057-A1 [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2004-04-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077672-A1 Anticarcinogenic, antiproliferative, and antitumor agents XDH, TOP2A, TOP1 CHEK1 943/4885CDK4 1989/4885CCND1 405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.